Ascentage Pharma Group International ( (HK:6855) ) has provided an update.
Ascentage Pharma has announced the inclusion of its novel drugs, lisaftoclax and olverembatinib, in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. Lisaftoclax, a Bcl-2 selective inhibitor, received its first recommendation for treating lymphoid malignancies, marking a significant milestone for the company in the field of hematological malignancies. Olverembatinib, a next-generation tyrosine kinase inhibitor, received an upgraded recommendation for treating leukemias in children and adolescents, highlighting its vital role in addressing BCR-ABL mutations. These developments enhance Ascentage Pharma’s industry positioning and expand its treatment options, potentially benefiting patients with specific cancer mutations.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing innovative therapies for cancer, chronic hepatitis B, and age-related diseases. The company specializes in creating novel drugs, including Bcl-2 selective inhibitors and tyrosine kinase inhibitors, with a market focus on addressing unmet clinical needs in oncology.
YTD Price Performance: -18.26%
Average Trading Volume: 4,457,325
Technical Sentiment Signal: Sell
Current Market Cap: HK$12.83B
For detailed information about 6855 stock, go to TipRanks’ Stock Analysis page.